Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $4.1 in the last session, down -2.84% from day before closing price of $4.22. In other words, the price has decreased by -$2.84 from its previous closing price. On the day, 0.71 million shares were traded. VYGR stock price reached its highest trading level at $4.25 during the session, while it also had its lowest trading level at $4.01.
Ratios:
We take a closer look at VYGR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.43. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Ferguson Toby sold 19,000 shares for $3.73 per share. The transaction valued at 70,870 led to the insider holds 138,914 shares of the business.
Ferguson Toby bought 19,000 shares of VYGR for $70,680 on Aug 18 ’25. On Apr 02 ’25, another insider, Ferguson Toby, who serves as the Chief Medical Officer of the company, sold 10,086 shares for $3.43 each. As a result, the insider received 34,595 and left with 157,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 227422112 and an Enterprise Value of 52033104. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.34 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 1.222 whereas that against EBITDA is -0.438.
Stock Price History:
The Beta on a monthly basis for VYGR is 0.92, which has changed by -0.28942806 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $8.27, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is 14.14%, while the 200-Day Moving Average is calculated to be 1.95%.
Shares Statistics:
According to the various share statistics, VYGR traded on average about 739.66K shares per day over the past 3-months and 847740 shares per day over the past 10 days. A total of 55.43M shares are outstanding, with a floating share count of 45.49M. Insiders hold about 17.99% of the company’s shares, while institutions hold 59.99% stake in the company. Shares short for VYGR as of 1756425600 were 2944562 with a Short Ratio of 3.98, compared to 1753920000 on 3214674. Therefore, it implies a Short% of Shares Outstanding of 2944562 and a Short% of Float of 6.329999999999999.
Earnings Estimates
The company has 10.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.34 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.77 and -$2.3 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$1.41, with 10.0 analysts recommending between -$0.48 and -$2.64.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $7.86M. It ranges from a high estimate of $12.5M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $24.63MFor the next quarter, 12 analysts are estimating revenue of $10.54M. There is a high estimate of $23.4M for the next quarter, whereas the lowest estimate is $5M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $45.13M, while the lowest revenue estimate was $21.67M, resulting in an average revenue estimate of $30.08M. In the same quarter a year ago, actual revenue was $80MBased on 12 analysts’ estimates, the company’s revenue will be $62.28M in the next fiscal year. The high estimate is $145.95M and the low estimate is $8M.
